30 closest matches · ranked by relevance
Long-term Safety of TIP
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs/SAEs Leading to Discontinuation of Study Drug and Deaths Over 12 Treatment Cycles…
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Time to All-Cause Mortality: Cohort A — 58.7; 35.8 Months — p=0.0001
HIV Infections
Primary: Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin — 1; 2; 6 participants
Cystic Fibrosis
Primary: Number of Participants With Treatment-emergent Adverse Events — 278; 176; 85; 61 participants
Benign Prostate Hyperplasia
Primary: Month 3 Results in the IPSS Score in Both Arms. — 12.57; 15.8 score on a scale
Primary Open Angle Glaucoma (POAG)
Primary: 5-year Annualized Rate (Percentage) of Sight-threatening Adverse Events, by Treatment Group — 0.19; 0.30 rate (percentage) of adverse events
Type 2 Diabetes Mellitus
Primary: Annual Rate of Change in FEV1 From Baseline to End of Study — -0.048 Liters per year
Glaucoma, Open-angle · Ocular Hypertension
Primary: Mean Intraocular Pressure — 16.5 millimeters mercury (mm Hg)
Pulmonary Infections · Pseudomonas Aeruginosa in Cystic Fibrosis
Primary: Percentage of Participants With Treatment Emergent Adverse Events, Serious Adverse Events (SAEs) and Deaths — 85.4; 31.2; 0.0 Percentage of participants
Aortic Valve Insufficiency · Aortic Valve Regurgitation · Aortic Valve Stenosis
Primary: Percentage of Participants With Freedom From Reoperation for Structural Valve Deterioration at 10 Years Post-Implant — 75.7 Percentage of Participants
FAP · Familial Amyloid Polyneuropathy · TTR
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Related to Study Drug — 100; 96.5; 36.0; 54.1 percentage of…
Migraine Disorders
Primary: Number of Participants With the Indicated Drug-related Adverse Events — 93; 46; 170; 19 participants
Pulmonary Arterial Hypertension
Primary: Number of Adverse Events — 440; 266; 41; 15 number of events
Glaucoma
Primary: Number of Patients That Achieve Target Intraocular Pressure Measured in mmHg — 8; 45; 22 Participants
Hearing Loss · Unilateral Hearing Loss · Total Unilateral Deafness
Primary: Long Term Safety — 22 participants
Pulmonary Disease, Chronic Obstructive
Primary: Number (%) of Patients With Drug-related AEs — 4.9; 5.0; 7.3 percentage of participants
Ocular Hypertension · Open Angle Glaucoma
Primary: Ocular Treatment Emergent Adverse Events — 9; 7; 9; 1 Number of Treatment-Emergent Events
Myopia
Primary: Central Endothelial Cell Density (All Eyes) — 2654.0; 2639.0; 2633.0; 2551.0 cells/mm^2
Retinopathy of Prematurity (ROP)
Primary: Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA) — 0; 0; 12; 19 Participants
Constipation Predominant Irritable Bowel Syndrome
Primary: Adverse Events in >2% Patients — 33; 7; 7; 11 participants
Presbyopia
Primary: Change (Increase) in Uncorrected Near Visual Acuity — 3.1 lines of visual acuity improvement
Glaucoma
Primary: Ocular Discomfort — 25.5 mm
Conductive Hearing Loss
Primary: Implant Stability — 66.7; 71.6; 67.4; 72.1 ISQ scores
Diabetes
Primary: Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) — 806; 1226; 704; 1715 Matched blood glucose readings — p=<0.05
Irritable Bowel Syndrome
Primary: Number of Participants With Treatment Related Adverse Events. — 205 Participants
Stress Urinary Incontinence
Primary: Mean Percentage of Pad Weight Gain (PWG) Change — 90.8; 98.5; 99.3; 89.3 Mean percentage of PWG change
Presbyopia
Primary: Primary Safety Measure - Partial or Complete Explantation — 2; 4 Eyes
Dyskinesias · Parkinson's Disease · Severe Motor Fluctuations
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs — 0; 0; 0; 0 participants
Aortic Stenosis
Primary: Death — 12 Participants
Ventricular Fibrillation · Ventricular Flutter · Sudden Cardiac Death
Primary: Number of Participants With Severe Intra-operative Complications at ICD Implant and/or Events at Follow up — 18; 16 Participants